Dermata Therapeutics (DRMAW) Competitors $0.02 +0.01 (+100.00%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends DRMAW vs. ATNFW, LBPSW, AARD, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aardvark Therapeutics (AARD), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. 180 Life Sciences 4D pharma Aardvark Therapeutics Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Dermata Therapeutics (NASDAQ:DRMAW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, community ranking, valuation, dividends and risk. Which has higher valuation and earnings, DRMAW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDermata TherapeuticsN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Does the MarketBeat Community favor DRMAW or ATNFW? Dermata Therapeutics and 180 Life Sciences both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformDermata TherapeuticsN/AN/A180 Life SciencesN/AN/A Does the media prefer DRMAW or ATNFW? In the previous week, Dermata Therapeutics and Dermata Therapeutics both had 1 articles in the media. Dermata Therapeutics' average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment Dermata Therapeutics Neutral 180 Life Sciences Neutral Is DRMAW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets Dermata TherapeuticsN/A N/A N/A 180 Life Sciences N/A N/A N/A SummaryDermata Therapeutics and 180 Life Sciences tied by winning 0 of the 0 factors compared between the two stocks. Remove Ads Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMAW vs. The Competition Export to ExcelMetricDermata TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$114.59M$5.66B$7.98BDividend YieldN/A3.69%4.89%4.03%P/E RatioN/A3.2123.8618.91Price / SalesN/A4,348.42382.37118.46Price / CashN/A13.0138.0534.62Price / BookN/A36.286.844.18Net IncomeN/A-$87.82M$3.19B$246.59M7 Day PerformanceN/A-0.99%-0.48%-1.69%1 Month PerformanceN/A-1.57%-6.62%-8.83%1 Year PerformanceN/A97.27%8.73%0.01% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMAWDermata TherapeuticsN/A$0.02+96.1%N/AN/A$0.00N/A0.008Gap UpATNFW180 Life SciencesN/A$0.01-12.0%N/A+31.3%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAARDAardvark TherapeuticsN/A$12.50-1.8%N/AN/A$0.00N/A0.0018Analyst ForecastNews CoveragePositive NewsAEHAWAesther Healthcare AcquisitionN/A$0.03+17.0%N/A-95.7%$0.00N/A0.002Gap UpAIMDWAinosN/A$0.09-3.3%N/A-12.3%$0.00$40,633.000.0040Positive NewsGap UpALVOWAlvotechN/A$2.19-0.5%N/AN/A$0.00$391.87M0.004Gap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03-2.9%N/AN/A$0.00N/A0.004Gap DownBFRIWBiofronteraN/A$0.08+36.4%N/A+6.0%$0.00$35.36M0.0070Positive NewsGap DownBTMDWbioteN/A$0.08-22.7%N/A-88.9%$0.00$193.06M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.11+0.1%N/A-94.6%$0.00N/A0.008Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AARD Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DRMAW) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
